The UK’s First Wegovy Weight-Loss Pill Goes on Sale

Thousands of Patients Expected to Begin Treatment as New Era of Obesity Care Begins

For the first time, people across the UK can now access a once-daily weight-loss tablet containing the same active ingredient as the injectable Wegovy treatment.

The oral version of Wegovy officially went on sale today through selected high street and online pharmacies, marking a significant milestone in the treatment of obesity. Thousands of eligible patients are expected to receive their first deliveries this week following online consultations and private prescriptions.

Unlike the injectable version, the tablet removes the need for weekly injections, a change that many experts believe could make treatment more acceptable to people who are reluctant to use needles.

What Is the Wegovy Pill?

The new tablet contains semaglutide, a GLP-1 receptor agonist that works by mimicking hormones released after eating.

It helps regulate appetite by increasing feelings of fullness, slowing stomach emptying and reducing hunger, making it easier for many people to consume fewer calories.

Semaglutide has already become well known through injectable medications such as Wegovy and Ozempic, with numerous clinical trials demonstrating significant weight loss when combined with healthy lifestyle changes.

The tablet offers an alternative method of taking the medication while delivering the same active ingredient.

Who Can Access It?

Initially, the tablet is only available through private healthcare providers and participating pharmacies following a medical assessment.

Patients must meet strict eligibility criteria, which generally include having obesity or being overweight with weight-related health conditions.

It is not currently available through routine NHS prescribing for weight management, although eligibility may expand as national guidance evolves.

Why This Matters

Obesity remains one of the UK’s biggest public health challenges. According to the latest government figures, around two-thirds of adults in England are living with overweight or obesity, increasing the risk of conditions including Type 2 diabetes, cardiovascular disease, sleep apnoea, osteoarthritis and some cancers.

Healthcare professionals have increasingly recognised obesity as a complex, chronic medical condition rather than simply a lifestyle issue. New medications such as semaglutide are becoming an important part of treatment alongside nutrition, physical activity and behavioural support. For many patients, the availability of a tablet may remove one of the biggest barriers to treatment.

It’s Not a Quick Fix

Healthcare professionals continue to stress that weight-loss medications are not miracle cures. The medication works best alongside sustainable lifestyle changes, including healthy eating, regular physical activity and ongoing clinical support.

Like all medicines, semaglutide can cause side effects. The most commonly reported include nausea, vomiting, diarrhoea, constipation and abdominal discomfort, particularly during the early weeks of treatment or following dose increases.

Regular medical supervision remains essential throughout treatment.

Looking Ahead

The arrival of an oral version of Wegovy represents another step in the rapidly evolving field of obesity medicine. As research continues and access expands, healthcare professionals are likely to see growing numbers of patients seeking advice about medical weight management. The challenge will be ensuring that treatment is delivered safely, equitably and alongside the wider support needed to achieve lasting improvements in health.

Q&A: Jill Shares Her Experience of Taking a GLP-1 Medication

Kathryn: There’s been a huge amount of discussion about weight-loss medications recently. Why did you decide to try one yourself?

Jill: I’d struggled with my weight for years, not massively, but I could never shift the two stone I wanted to lose. Like many people, I’d tried countless diets and I’d lose weight, then put it back on again. Eventually I wanted to see whether a medically supervised GLP-1 medication could help me break that cycle.

Kathryn: What surprised you most?

Jill: Probably how quiet my mind became around food. People often talk about “food noise”, and I didn’t really understand what they meant until it disappeared. I wasn’t constantly thinking about what I was going to eat next.

Kathryn: Was it easier than you expected?

Jill: Not really. Living in the United States meant I was able to access the once-daily tablet before it became available in the UK, and for me it has been a complete game changer. Before that, I tried the once-weekly injections, but they often left me feeling so unwell that I’d spend an entire day in bed after taking them. Thankfully, I haven’t experienced that with the tablets. Everyone responds differently, but they’ve suited me much better.

That said, there’s a misconception that these medications do all the work for you. They don’t. You still have to make good food choices and build healthier habits. I also experienced nausea, particularly when I increased my dose after the first month. It became clear my body wasn’t ready, so I spoke to my clinician and went back down to the lower dose, which was the right decision for me.

I’ve also learnt that some foods simply don’t agree with me anymore, especially richer or heavier meals. It’s definitely been a learning curve, but overall the tablets have made my weight-loss journey much more manageable.

Kathryn: Would you recommend it?

Jill: I’d recommend that anyone interested has an honest conversation with a healthcare professional. These medications aren’t right for everyone, but for the right person they can be life-changing. It’s important that people understand both the benefits and the challenges before starting.

Kathryn: Has taking the medication changed the way you think about obesity or your overall health?

Jill: Absolutely. It’s made me realise that obesity is far more complex than simply eating less and moving more. There are biological, psychological and environmental factors involved, and for many people these medications provide another tool rather than a quick fix.

One thing I’ve noticed personally, although I don’t know whether it’s connected to the medication, is that my perimenopause symptoms seem to have improved since I started taking it. My muscle aches have almost disappeared, and my hot flushes are nowhere near as frequent as they were before. I can’t say for certain that the medication is the reason. It could be related to losing weight, eating differently, or it could simply be a coincidence. But it’s something I’ve noticed and will be keeping an eye on as my journey continues.

What I do know is that I feel healthier, I have more energy, and I’ve developed a much greater appreciation of just how complex obesity really is.

Have a question for Jill?

Kathryn will be putting your questions to Jill in a future Q&A. Send your question to newsdesk@dailyround.news and it could be featured in an upcoming Daily Round article.